Skip to main content
Smart Investors Daily
XL

NASDAQ · XLO

Xilio Therapeutics, Inc.

Healthcare · Biotechnology

$8.08

Down-$0.38 (-4.64%)

Updated Nov 17, 2026, 1:28 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
37.56M
P/E ratio
-2.44
Dividend yield
0.00%
52-week range
$6.47 – $11.30
Volume
7.58K
Avg. volume
620.67K

Price performance · XLO

XLO price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

XLO closed at $8.08 after 20 trading sessions, down 3.06% for the selected period.

Last close
$8.08
Period change
-3.06%
Period low
$7.31
Period high
$9.00
Daily close
View OHLC price history
XLO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$7.96$8.075$7.60$8.0757.58K
Nov 12, 2026$8.25$8.25$7.96$8.249.09K
Nov 11, 2026$8.82$8.85$8.40$8.473.53K
Nov 10, 2026$8.82$8.82$8.53$8.533.08K
Nov 9, 2026$8.8567$9.00$8.57$9.0010.72K
Nov 6, 2026$8.24$8.69$8.24$8.626.78K
Nov 5, 2026$8.45$8.65$7.775$8.5027.23K
Nov 4, 2026$8.425$8.86$8.425$8.7111.79K
Nov 3, 2026$8.03$8.85$7.935$8.6824.49K
Nov 2, 2026$7.49$8.065$7.49$7.996.84K
Oct 30, 2026$7.0501$8.0889$7.0501$8.037.91K
Oct 29, 2026$8.20$8.20$7.77$7.772.71K
Oct 28, 2026$7.81$8.19$7.57$8.0116.68K
Oct 27, 2026$7.855$8.09$7.17$8.0127.93K
Oct 26, 2026$7.54$8.6368$7.05$7.3133.45K
Oct 23, 2026$8.06$8.245$7.51$7.5716.25K
Oct 22, 2026$8.45$8.48$8.00$8.0315.37K
Oct 21, 2026$8.545$9.05$8.2487$8.4336.27K
Oct 20, 2026$8.25$8.84$8.25$8.5413.51K
Oct 19, 2026$8.69$8.735$8.33$8.3311.49K

Latest XLO news

The latest Smart Investors Daily articles mentioning XLO.

XLO research

Overview

Company profile and research snapshot.

Company profile

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.00
Implied upside
—
Analysts
6
XLO recent ratings
DateFirmRatingTarget
Oct 21, 2026Raymond JamesOutperform—
Aug 6, 2025Leerink PartnersOutperform—
Nov 8, 2024Raymond JamesOutperform—
May 30, 2023Chardan CapitalBuy—
May 11, 2023Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the fourth quarter of 2027 Advancing XTX602, a dual-masked CLDN18.2-targeting multi-specific TCE with co-stimulation, and XTX701, a masked PSMAxSTEAP1-targeting multi-specific TCE with co-stimulation, toward planned IND applications in the fourth quarter of 2027 WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWI

Yahoo · Nov 3, 2026

Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference

WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at 2:40 p.m. ET. A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at ir.xili

Yahoo · Oct 26, 2026

Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC

XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors Anticipate reporting initial Phase 1 data in the fourth quarter of 2027 Plan to present a trial-in-progress poster for XTX501 at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting WALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncolo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.